Cases
Spark Therapeutics, Inc. (ONCE)
Merger
Overview
Overview
- Date:
- 2/25/2019
- Company Name:
- Spark Therapeutics, Inc.
- Stock Symbol:
- ONCE
- Company Name - Buyer:
- Roche Holding AG
- Status:
- Closed/Complete
- Merger Announcement Date:
- 2/25/2019
NEW YORK, February 25, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Spark Therapeutics, Inc. (NASDAQ: ONCE) on behalf of stockholders concerning the proposed acquisition of the company by Roche Holding AG.
Pursuant to the proposed transaction, announced on February 25, 2019 and valued at $4.3 billion, Spark stockholders will receive $114.50 in cash for each share of Spark common stock owned. The investigation focuses on whether Spark and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Spark shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
Pursuant to the proposed transaction, announced on February 25, 2019 and valued at $4.3 billion, Spark stockholders will receive $114.50 in cash for each share of Spark common stock owned. The investigation focuses on whether Spark and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Spark shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.